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In order to explore the potential of HLA-independent T cell therapy for human
cytomegalovirus (HCMV) infections, we developed a chimeric antigen receptor (CAR)
directed against the HCMV encoded glycoprotein B (gB), which is expressed at
high levels on the surface of infected cells. T cells engineered with this anti-gB
CAR recognized HCMV-infected cells and released cytokines and cytotoxic granules.
Unexpectedly, and in contrast to analogous approaches for HIV, Hepatitis B or Hepatitis
C virus, we found that HCMV-infected cells were resistant to killing by the CAR-modified
T cells. In order to elucidate whether this phenomenon was restricted to the use of
CARs, we extended our experiments to T cell receptor (TCR)-mediated recognition of
infected cells. To this end we infected fibroblasts with HCMV-strains deficient in viral
inhibitors of antigenic peptide presentation and targeted these HLA-class I expressing
peptide-loaded infected cells with peptide-specific cytotoxic T cells (CTLs). Despite
strong degranulation and cytokine production by the T cells, we again found significant
inhibition of lysis of HCMV-infected cells. Impairment of cell lysis became detectable
1 day after HCMV infection and gradually increased during the following 3 days. We
thus postulate that viral anti-apoptotic factors, known to inhibit suicide of infected host
cells, have evolved additional functions to directly abrogate T cell cytotoxicity. In line with
this hypothesis, CAR-T cell cytotoxicity was strongly inhibited in non-infected fibroblasts
by expression of the HCMV-protein UL37x1, and even more so by additional expression
of UL36. Our data extend the current knowledge on Betaherpesviral evasion from T
cell immunity and show for the first time that, beyond impaired antigen presentation,
infected cells are efficiently protected by direct blockade of cytotoxic effector functions
through viral proteins.
Keywords: herpesvirus, cytomegalovirus, immune evasion, chimeric antigen receptor, anti-apoptotic, UL36,
UL37x1, glycoprotein B
Abbreviations: CAR, chimeric antigen receptor; CEA, carcinoembryonic antigen; chNKG2D, chimeric NKG2D receptor;
CHX, cycloheximide; CMA, Concanamycin; EpCAM, epithelial cell adhesion molecule; Eu, Europium; gB, glycoprotein B;
HBV, hepatitis B virus; HCMV, human cytomegalovirus; HCV, hepatitis C virus; HFF, human foreskin fibroblasts; MOI,
multiplicity of infection; p.i., post infection.
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INTRODUCTION
Human cytomegalovirus infection after hematopoietic stem
cell transplantation is associated with substantial morbidity
and mortality. Antiviral chemotherapy is prophylactically and
preemptively used early after transplantation but frequently
results in toxicity and selection of drug resistant viruses.
Moreover, it does not prevent all complications associated with
HCMV (Boeckh and Ljungman, 2009; Boutolleau et al., 2009).
Adoptive transfer of HCMV-specific memory T cells has been
successfully applied, however, generation of specific T cells from
seronegative donors was accomplished only recently (Hanley
et al., 2015; Nicholson and Peggs, 2015). We hypothesized that
HCMV could be targeted in an HLA-independent manner by
CAR-T cells directed against intact viral proteins, such as gB,
that are displayed on the surface of HCMV-infected cells. This
strategy would circumvent the time-consuming enrichment and
expansion of preexisting HCMV-specific memory T cells, and
it would ease the application of adoptive T cell therapy in the
high-risk constellation of an HCMV seronegative donor and an
HCMV seropositive transplant patient.
The CAR approach has been applied early for treatment
of HIV, where some efficacy has been shown even in patients
(Mitsuyasu et al., 2000). Recently, the efficacy of CAR-
expressing T cells to eliminate virus-infected cells has also been
demonstrated for Hepatitis B and Hepatitis C (Krebs et al., 2013;
Sautto et al., 2016). We have previously constructed a functional
CAR targeting the conserved AD1 region of gB, which mediated
T cell activation in response to HCMV-infected cells (Full et al.,
2010).
Interestingly, systematic investigation of the cytotoxic
potential of these cells showed that T cells equipped with this
CAR could not directly eliminate cells infected with this virus.
This was unexpected, since our approach was designed to
circumvent the known Betaherpesvirus evasion of T cell killing
by reduced MHC class I antigen-presentation (Crough and
Khanna, 2009; Halenius et al., 2015).
Our study with CAR-T cells now explicitly shows that a virus
can evade T cell immunity by blockade of cytotoxic effector
functions and that this can be directly mediated by a viral
protein. To our knowledge this is the first evidence of such a
mechanism, which likely is not confined to HCMV but could be
more common in viral immune evasion.
MATERIALS AND METHODS
Cells and Cell Lines
Purification of PBMCs from leukapheresis obtained from
voluntary healthy donors was undertaken by density gradient
centrifugation using Ficoll. T cells were isolated from PBMCs
by negative selection of CD3pos cells using the Dynabeads
Untouched HumanTM T cell Kit (Life Technologies) according
to the manufacturer’s instructions. HFF were isolated from
foreskin of circumcised donors after mechanic disruption by
enzymatic digestion with 5 mg/ml Collagenase D, 25 U/ml
Dispase, and 0.05% Trypsin/EDTA and were cultured in R-10
medium, consisting of RPMI GlutaMAXTM (Life Technologies)
supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml
streptomycin. Isolated HFF were used for experiments until
passage 20. Written informed consent was obtained from
every voluntary donor and each study protocol was approved
by the local ethics committee (Friedrich-Alexander-Universität
Erlangen-Nürnberg no. 2247, Medizinische Universität Wien no.
514/2011). Phoenix and 293T cells were cultured in DMEM
(Life Technologies) supplemented with 10% FCS and 100 U/ml
penicillin and 100 µg/ml streptomycin, and the hybridoma
cell line “gB 27-287” (a kind gift from M. Mach, Institute of
Virology, Universitätsklinikum Erlangen, Germany) was kept in
R-10.
Activation and Expansion of T Cells
T cells were stimulated with either Human T-Activator
CD3/CD28 Dynabeads (Life Technologies) according to the
manufacturer’s instructions or with peptide-loaded matured
Dendritic cells (DC). Briefly, monocytes were enriched by
adherence in RPMI GlutaMAXTM supplemented with 2% human
serum for 2 h and cultivated afterward in R-10 supplemented
with 500 U/ml IL-4 and 500 U/ml IL-4 GM-CSF (both from
Peprotech). On day 5, DCs were maturated by the addition of
250 U/ml IL-4, 250 U/ml IL-4 GM-CSF, 10 ng/ml IL-1β (R&D
Systems), 10 ng/ml TNF (Miltenyi), 1000 U/ml IL-6 (Peprotech),
and 1 µg/ml Prostaglandin E2 (Sigma). Mature DCs were loaded
on day 7 with 5 µg/ml of the HLA-A∗0201 restricted EBV-
BMLF1 peptide GLCTLVAML (Genscript). Peptide-pulsed DCs
were mixed with T cells at a ratio of 1:4 for stimulation of
EBV-specific T cells and seeded at a density of 0.5 × 106 T
cells/ml RPMI GlutaMAXTM supplemented with 10% human
serum, 100 U/ml IL-2 (Peprotech), 50 µM β-mercaptoethanol,
100 U/ml penicillin and 100 µg/ml streptomycin, 1 mM sodium
pyruvate, 1x vitamins and 1x non-essential amino acids (Gibco).
Stimulation of T cells with mature peptide-pulsed DCs was
performed weekly. After the second stimulation CD8pos T cells
were positively selected using Dynabeads FlowComp Human
CD8 Kit (Life Technologies) according to the manufacturer’s
protocol and were cultured after the third antigen-specific
stimulation in medium supplemented with 10% FCS instead
of 10% HS. CD3/CD28-activated T cells were kept in R-10
supplemented with 100 U/ml IL-2, 50 µM β-mercaptoethanol,
100 U/ml penicillin and 100 µg/ml streptomycin, 1 mM sodium
pyruvate, 1x vitamins and 1x non-essential amino acid. EBV-
specific as well as CD3/CD28-activated T cells were used between
days 25 and 32 for experiments.
Viruses
Human cytomegalovirus strain AD169 encoding GFP was
provided by M. Marschall (Universitätsklinikum Erlangen,
Erlangen, Germany; Marschall et al., 2000), GFP-recombinant
strains AD169 1US2-11 (Falk et al., 2002) and Towne
1US1-12 (Marchini et al., 2001) were kind gifts from B.
Plachter (Universitätsmedizin, Johannes Gutenberg-Universität
Mainz, Mainz, Germany) and H. Zhu (Rutgers New Jersey
Medical School, Newark, USA), respectively. Infectious HCMV
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supernatants were obtained by infection of semi-confluent HFF
with an MOI 0.1 and collected after 11–14 days, centrifuged, and
stored at −80◦C until further use. Titration of HCMV stocks
was performed by using the limiting dilution method according
to Reed and Munch. In the experiments, confluent HFF were
infected with MOI 5 unless otherwise specified and used at the
indicated time points after infection.
Flow Cytometric Analysis
Flow cytometric analysis of the T cell phenotype was performed
using the following mAbs: CD3 (clone SK7), CD4 (clone OKT4,),
CD8 (clone RPA-T8), CD27 (clone M-T271), CD28 (clone
CD28.2), CD56 (clone NCAM1.2), CD62L (clone DREG-56).
CAR-expression in T cells was detected with a biotinylated anti-
human IgG mab (clone JDC-10) continued by incubation with
PE-conjugated streptavidin. Cell surface expression of HCMV-gB
in viable HFF (propidium iodideneg or 7-AADneg) was detected
by incubation with supernatants from hybridoma gB 27-287
and a PE- or APC-conjugated anti-mouse antibody. HLA-A∗02
surface expression in viable HFF was determined by using an
APC-labeled HLA-A∗02 antibody (clone BB7.2). Non-infected
and HCMV-infected HFF were blocked with human serum
from a HCMV-seronegative individual before staining with
antibodies. Intracellular expression of perforin and granzymes
in T cells or UL37x1 in HFF, respectively, was analyzed after
fixation with formaldehyde and permeabilization with saponin
followed by incubation with monoclonal antibodies directed
against perforin (clone dG9), granzyme A (clone CB9), granzyme
B (clone GB11), granzyme K (clone G3H69), granzyme M (clone
4B2G4), and the myc-Tag (clone Sc-40), respectively. Cells were
counted using Accu chek counting beads (Life Technologies),
whereby propidium iodide or Annexin V-FITC was added
for exclusion of dead cells. BD LSR Fortessa was used for
measurements and BD FacsDiva and FlowJo were used for data
analysis.
In Vitro Transcription and
Electroporation of mRNA
DNA templates for in vitro transcription of mRNA were
generated by linearization of plasmids pGEM4Z encoding
the CARs directed against HCMV-gB, CEA, and chNKG2D
(Full et al., 2010; Lehner et al., 2012). The mRNA encoding
for UL36 was generated from a PCR product amplified from
pLV-EF1α-MCS-UL36-IRES-puro kindly provided by E. Mocar-
ski (Emory University School of Medicine, Atlanta, USA;
McCormick et al., 2010) using two specific primer pairs for
amplification of UL36 exons (gcttacgtctgctgtcaggag, cgtgaggaat
ttcgacatttaatacgactcactatagggttccatttcaggtgtcgtgacgataccgtcgagatt
aattaaatttcagttgttcatgtaaacgtgtg, tcctgacagcagacgtaagcaccttgcgaac
agacggtg) followed by Gibson assembly (NEB). The
fusion construct of the gB-ectodomain and EpCAM
transmembrane/cytoplasmic proportion was transcribed from
a purified PCR product, which was amplified from a bacmid
encoding a respective recombinant murine cytomegalovirus.
In vitro mRNA transcription was performed with the
mMessage mMachine T7 Ultra Kit (Ambion) according to
the manufacturer’s instructions followed by RNA purification
with the RNeasy Kit (Qiagen). For electroporation of the
mRNA, T cells and 293T cells were resuspended in phenol-free
Opti-MEM at a density of 8 × 107/ml (T cells) or 0.5 × 107/ml
(293T cells). HFF were detached with Trypsin/EDTA and
resuspended at a density of 0.5 × 106/400 µl in GenePulser R©
Electroporation Buffer Reagent (Bio-Rad). Electroporation was
performed with 100 µl cell suspension (T cells and 293T cells)
or 400 µl cell suspension (HFF) in a 4 mm electroporation
cuvette after addition of 10 µg mRNA using the GenePulser
square wave protocol (Gene Pulser Bio-Rad, conditions: 500 V
and 5 ms for T cells and HFF, 500 V and 3 ms for 293T
cells).
Transduction of HFF with Viral Vectors
Lenti- or retroviral particles containing supernatants were
produced by transfection of 293T or Phoenix cells, respectively.
The lentiviral vector pWPI encoding EpCAM-gB was co-
transfected with psPAX (Addgene 12260) and MD2.G (Addgene
12259) in a ratio of 4:3:1 in 293T cells using 3.5 µg/ml PEI.
Phoenix cells were transfected with the retroviral vector pLNCX
UL37x1 or pLNCX GFP [kindly provided by McCormick et al.
(2005)] and pMD2.G (4:1 ratio) by addition of 3.5 µg/ml PEI.
Viral supernatants were harvested after 48 h, cleared of cell debris,
concentrated using Spin-X R© UF Concentrator (100,000 Dalton;
Corning), aliquoted and stored at −80◦C until further use.
HFF were spinoculated three times with retroviral supernatants
diluted 1:1 with fresh media (1500 × g, 33◦C, 4 h). Transduced
cells were either selected by addition of 4 µg/ml Geneticin
(pLNCX-vector) or by flow cytometric cell sorting using BD
FACSAria, respectively.
Cytotoxicity Assays
The lytic potential of T cells was analyzed in a non-radioactive
Eu-release assay (Blomberg et al., 1996) or by determination
of apoptotic target cells using Annexin V by flow cytometry.
Eu release assay: target cells were detached with EDTA and
labeled with Eu as previously described (Lehner et al., 2007).
2500 Eu-labeled target cells were co-incubated with effector T
cells at the indicated effector:target(E:T)-ratio for 4 h at 37◦C.
Eu-release by target cells into supernatant was analyzed by
addition of 200 µl Enhancement Solution (Perkin Elmer) to
25 µl co-culture supernatant using time-resolved fluorometry
(TRF; Victor, Wallac). Specific target cell lysis was calculated
using the following formula: specific lysis [%] = (Eu release in
co-culture – spontaneous Eu release)/(maximum Eu release –
spontaneous Eu release) ∗100. Flow cytometric apoptosis assay:
Target cells were seeded at a density of 10,000 target cells/96-well
after detachment. T cells were labeled with 10 µM SNARF-1 R©
(carboxylic acid acetate succinyl ester; Life Technologies) in PBS
for 15 min and added to the target cells at the indicated E:T-
ratios. After 4 or 20 h of co-culture at 37 ◦C target cells were
harvested with Trypsin/EDTA, washed once with PBS 0.2% HA,
0.02% Na-Azide and resuspended in 1x Annexin binding buffer
(eBioscience). Cells were analyzed after addition of 5 µl Annexin
V and 5 µl 7-AAD in a flow cytometric analysis. Apoptotic cells
were determined by exclusion of T cells and gating on Annexin
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Vpos target cells. Only GFPpos cells were considered in the
case of HCMV-infected HFF. Apoptosis in UL37x1-transduced
HFF fraction was calculated after flow cytometric analysis of
intracellular UL37x1-myc expression in HFF (60.4–94.8%) using
the formula: Annexin Vpos cells [%] = 100/mycpos HFF [%] ∗
(Annexin Vpos UL37x1-HFF detected by FACS [%]–X); X= (100
– mycpos [%]) ∗ Annexin Vpos mock-HFF detected by FACS
[%]/100.
Degranulation Assay
Flow cytometric analysis of CD8pos T cell degranulation was
performed by extracellular staining of CD107a as previously
described (Betts et al., 2003). Briefly, 50,000 T cells were co-
incubated with 50,000 target cells in the presence of PE-labeled
CD107a in RPMI supplemented with 10% FCS and 10% HS.
Monensin was added to a final concentration of 5 µM after 1 h of
co-incubation at 37◦C. After 4 h, the T cells were harvested and
additionally stained with antibodies directed against CD3, CD4
and CD8.
ELISA
After co-culturing 60,000 T cells with 30,000 target cells in 200 µl
RPMI1640 for 4 h, the amounts of secreted IFN-γ and TNF were
determined using ELISA kits from eBioscience and Mabtech,
respectively.
Statistical Analysis
Statistical significance was calculated using the paired two-tailed
Student’s t-test (∗∗∗ = p< 0.001, ∗∗ = p< 0.01, ∗ = p< 0.05).
RESULTS
CAR-T Cells Directed against HCMV-gB
Do Not Lyse HCMV-Infected Cells
We previously demonstrated that our HCMV-gB specific CAR
is capable of mediating efficient lysis of gB transfected 293T
cells and of inducing cytokine release from the CAR-T cells
in response to HCMV-infected HFF (Full et al., 2010). In
previous unpublished experiments with anti-CD3 activated T
cells, however, we observed weak or absent lytic activity of CAR-
T cells against HCMV-infected HFF 3 days after infection (data
not shown), although gB was strongly expressed on the surface of
infected cells at that time point (Supplementary Figure S1A).
To investigate whether the observed absence of lysis of
infected cells expressing the target antigen was due to low
T cell efficacy or a peculiarity of HCMV infection, we
decided to thoroughly investigate this issue by conducting
experiments with effector T cells activated (A) in an antigen-
independent manner by αCD3/αCD28 antibody-coated beads,
or (B) enriched from a preexisting memory pool of Epstein-
Barr virus (EBV)-specific effector T cells. For the latter we
employed a previously established culture system relying on
weekly restimulation with peptide-loaded DC, which resulted
in efficient expansion of antigen-specific cytotoxic memory T
lymphocytes (CTLs; routinely above 50%; Supplementary Figure
S1B; Lehner et al., 2007). The cultures were depleted of NK
cells, and if necessary sorted for CD8pos T cells, finally resulting
effector cell populations consisting of 56.3–98.8% CD8pos T
cells (αCD3/αCD28-activated T cells) or 92.2–98.2% CD8pos
T cells (EBV-specific CTLs, not shown), and < 1.0% NK
cells. EBV-specific effectors were additionally chosen because
of a more advanced differentiation stage (loss of CD62L and
CD45RA; upregulation of CD45RO; Supplementary Figures
S1C,D). A detailed analysis of the expression profile of the
cytotoxic effector molecules perforin and granzymes A, B, K,
and M, however, showed a pattern which was very similar to
that of αCD3/αCD28-activated T cells (Supplementary Figure
S1E).
The polyclonally activated and EBV-specific T cells were
transiently transfected with either the gB-specific CAR or an
irrelevant CAR specific for the CEA by electroporation of
CAR-encoding mRNA (CAR expression shown in Figure 1A;
Hombach et al., 2001). Lytic activity of these CAR-T cells
was determined 1 day after electroporation using HCMV-
infected HFF and gB-expressing 293T as target cells (gB-
expression is shown in Figure 1B). Unexpectedly, neither type
of effector T cells achieved substantial lysis of HFF 4 days after
infection (Figure 1C), not even with an effector:target(E:T)-
ratio of 25:1. However, the same effectors strongly lysed
gB-expressing 293T cells, although gB-expression in these
target cells was lower than on infected HFFs (Figure 1D).
Notably, non-specific killing, which was frequently observed
with non-infected fibroblasts, also seemed to be inhibited
by HCMV, since it never occurred in infected fibroblasts
(Figure 1C).
We further determined the level of T cell degranulation
and cytokine production in order to exclude that the observed
lack of lysis of HCMV-infected HFF is due to inhibition of T
cell activation. Figure 2A illustrates that the gB-specific CAR
triggers degranulation in both effector populations in co-culture
with infected HFF, whereas the T cells did not degranulate
in the control conditions. Similarly, IFN-γ production was
triggered by the gB-specific CAR in response to infected
HFF, whereas there was no or low-level production under
control conditions (Figure 2B); analysis of TNF showed the
same pattern (data not shown). Notably, the readout of these
effector functions was congruent between the αCD3/αCD28-
activated T cells and the EBV-specific CTLs, and showed a
high specificity for gB-recognition, in contrast to cytotoxicity
with frequently also unspecific lysis of non-infected HFF
(Figure 1C).
Together, these data clearly show that both polyclonally
expanded as well as antigen-specific memory T cells, when
engrafted with a gB-specific CAR, cannot lyse infected HFF
despite detectable CAR-mediated specific activation of the T cells.
HCMV also Blocks TCR-Mediated Lysis
Despite Activation of T Cells
In the next step we wanted to exclude that a possible defective
function of our gB-specific CAR was responsible for the observed
lack of lysis. For this reason we again employed EBV BMLF1-
peptide-specific CTLs, which this time, however, were directed
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FIGURE 1 | Lysis of HCMV-infected HFF by CAR-T cells is strongly reduced. (A) The histograms shows the expression of the different CARs in
αCD3/αCD28-activated or EBV-specific T cells, respectively, 20 h after mRNA electroporation of a representative donor (EBV-specific T cells n = 6; 4 donors;
αCD3/αCD28-activated n = 3; 3 donors). (B) Flow cytometric analysis of the gB-expression in 293T cells, gB-expressing 293T (293T-gB) cells, non-infected and
HCMV-infected HFF. Shown is a representative histogram of one experiment (n = 3). (C,D) The diagrams show the lytic potential of redirected
αCD3/αCD28-activated or EBV-specific T cells targeting HCMV-infected HFF (C) or gB-expressing 293T (293T-gB; (D) analyzed in a 4 h Eu release assay (E:T-ratio
referring to CD8pos T cells = 25:1). 293T cells, non-infected HFF were used as target cell controls, CEA-CAR-expressing EBV-specific T cells were used as controls
for CAR-T cells. (B–D) HCMV-infected HFF in all shown experiments were used at 4 days after infection (AD169, MOI 5).
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FIGURE 2 | CAR-T cells are activated by HCMV-infected HFF. (A) The histograms show the degranulation of CD8+ CAR-expressing αCD3/αCD28-activated or
EBV-specific T cells, respectively, after co-incubation with non-infected and HCMV-infected HFF, as analyzed by flow cytometric detection of CD107a cell surface
expression. (B) Levels of IFN-γ secreted into the supernatants of co-cultures of CAR-modified T cells and non-infected or HCMV-infected, respectively. (A,B)
HCMV-infected HFF in all shown experiments were used 4 days after infection (AD169, MOI 5).
via their TCR to HLA-A∗0201 matched fibroblasts loaded with
a saturating concentration of the same BMLF1-peptide that was
used for T cell enrichment. In addition, we used a recombinant
variant of the HCMV-strain Ad169 (Ad1691US2-11), which
contained extended deletions in the US-gene region encoding the
known viral inhibitors of antigenic peptide presentation, in order
to prevent down-regulation of MHC class I molecules during
infection (Supplementary Figure S2A; Jones et al., 1995; Besold
et al., 2009).
In this CAR-independent experimental setup HCMV-
infection again resulted in a striking resistance of the HFF to lysis
by the T cells (Figure 3A). Lysis-inhibition of the peptide-loaded
HFF gradually increased in the course of infection and became
significant already 1 day after infection at the lowest E:T-ratio of
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FIGURE 3 | T cell receptor-mediated lysis of HFF is reduced by HCMV starting from 1 day after infection. (A) TCR-mediated lysis of non-infected and
HCMV-infected HFF (AD169 1US2-11, MOI 5) by EBV-specific T cells (E:T = 1:1; 5:1; 25:1) was analyzed in a 4 h Eu release assay at the indicated time points after
infection (p.i. = after infection; three technical replicates with each donor). Target cells were pulsed with BMLF1-peptide (2 µM GLCTLVAML) for 2 h before
co-incubation with EBV-specific T cells or left untreated. (B) The histograms show the degranulation of EBV-specific T cells after co-incubation with either untreated
or peptide-pulsed non-infected and HCMV-infected HFF (AD169 1US2-11, MOI 5, d4 p.i.), as analyzed by flow cytometric detection of CD107a at the cell surface.
(C) Levels of IFN-γ secreted into the supernatants of co-cultures of EBV-specific T cells and peptide-pulsed or non-pulsed HFF, respectively (non-infected or
1–4 days after infection with AD169 1US2-11, MOI 5, as indicated).
1:1. Despite the strong gradual increase in inhibition, residual
lysis obtained with an E:T of 25:1, however, was still significant
even 4 days after infection. Importantly, the observed inhibition
was not accompanied by any inhibition of T cell activation, as
quantified by degranulation and IFN-γ secretion (Figures 3B,C).
The levels of secreted IFN-γ thereby were reproducibly markedly
higher than obtained with gB-CAR-mediated recognition
(Figure 2B), likely reflecting enhanced T cell activation, which
would explain the observed increased cytotoxicity.
Reduced lysis of HCMV-infected HFF by peptide-specific
CTLs is well-known, however, this has been attributed to
impaired peptide-presentation and thus reduced TCR signaling
(Allart et al., 2003; Manley et al., 2004; Besold et al., 2007, 2009;
Kim et al., 2011; Ameres et al., 2014). Our data obtained with
the US-gene-deleted HCMV-strain Ad1691US2-11 circumvents
this known mechanism experimentally and strongly suggest an
additional immune escape mechanism of HCMV.
Lysis Inhibition Occurs with Different
HCMV-Strains and also after Extended
Co-culture Periods with the T Cells
To further substantiate our finding, we conducted experiments
with the HCMV Towne strain, which, like Ad169, was available
with deleted US-gene region. This circumstance allowed the
direct comparison of strains Towne and Ad169 both in our
CAR-based system and in our experimental EBV peptide specific
system dependent on genuine TCR-mediated recognition.
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Additionally, we tested the possibility that cell death could
be efficiently triggered, but progresses with slower kinetics, by
prolonging the co-culture-period.
For this set of experiments we again used EBV-BMLF1-specific
CTLs and directed them either via their own TCR or by the
transiently expressed gB-specific CAR against the HFF. Induction
of apoptosis in the HFF (non-infected or 3 days after infection)
was determined after co-culture with T cells for 4 and 20 h by
flow cytometry. Flow cytometry was chosen, because it allowed
us to monitor cells after extended periods of co-culture, which
was not possible with the Eu-release assay.
The lysis of peptide-loaded HFF by EBV-specific CTLs
during 4 h of co-culture was significantly inhibited 3 days
after infection with Ad1691US2-11 (compared to non-
infected HFF, Figure 4A), which is in accordance with our
previous experiments (Figure 3A). Infection of the HFF with
Towne1US1-12 also resulted in lower levels of lysis by the
EBV-CTLs, however, this reduction (compared to non-infected
HFF) did not reach statistical significance. When we extended
the co-culture period to 20 h, inhibition of lysis of Ad1691US2-
11-infected HFF (compared to non-infected HFF) was still
present (Figure 4A). However, peptide-specific lysis of the HFF
(i.e., lysis of peptide pulsed versus non-pulsed HFF) generally
increased and became significant for Ad1691US2-11-infected
HFF also at the E:T of 5:1.
When we directed, in parallel experiments, the EBV-specific
CTLs by transfection of the gB-specific CAR against the infected
HFF, we could not find significant CAR-specific cell death
induction in any condition, not even after 20 h of co-culture
(Figure 4B). This is in line with a lower degree of activation of the
EBV-CTLs, when they were directed to the infected HFF via the
gB-CAR, compared to activation of the EBV-CTLs in response to
HFF loaded with saturating amounts of BMLF1-peptide. These
differences in activation correspond to the observed different
levels of degranulation (Figures 4C vs. 4D); in the case of gB-
CAR-directed CTLs this seems to correlate with the levels of
gB-expression on the infected HFF (Supplementary Figure S2B).
Taken together, these data indicated that lysis-inhibition is a
general function of the Betaherpesvirus prototype HCMV as it
is not restricted to a single laboratory strain, and it can also be
demonstrated under conditions of prolonged co-culture.
HCMV-Encoded Proteins Abrogate T Cell
Cytotoxicity
The genome of HCMV encodes several anti-apoptotic proteins
and untranslated RNAs, which are thought to delay suicide of
infected host cells (Brune, 2011). Among them, the proteins UL36
and UL37x1 (vMIA) are known to block death receptor-mediated
apoptosis and to inhibit cell death induction at different levels
(Goldmacher et al., 1999; Skaletskaya et al., 2001; McCormick
et al., 2005). We hypothesized that these proteins might also
contribute to inhibition of T cell cytotoxicity.
Skaletskaya et al. (2001) already speculated about a role for
UL36, based on its ability to block activation of caspase-8, in
the inhibition of T cell cytotoxicity (Skaletskaya et al., 2001).
However, the HCMV Ad169 strains used in our study encode
an inactive mutant of UL36 (sequencing data not shown) but
still mediated resistance to lysis by T cells, indicating that further
viral proteins are involved. Furthermore, cytotoxic T cells can
induce target cell death independent from caspases by releasing
granzymes (Chowdhury and Lieberman, 2008). Nevertheless, we
considered it important to directly investigate the ability of UL36
to block T cell cytotoxicity. Furthermore, we also considered the
possibility that functional redundancy of multiple factors could
prevent loss of function by inactivation of only one factor, as, e.g.,
UL36. Combined inactivation of these factors in HCMV result
in early host cell death (McCormick et al., 2005), and was thus
not an option for studying the influence on T cell cytotoxicity in
our experiments. Instead, we conducted co-culture experiments
of T cells with engineered non-infected HFF that expressed these
HCMV-proteins separately and in combination.
Figure 5A shows the results of control experiments that
confirm the protective function of the proteins, as previously
reported, by blocking death-receptor mediated apoptosis
triggered by an agonistic anti-Fas-antibody in combination
with CHX (as previously reported by (Goldmacher et al., 1999;
Skaletskaya et al., 2001; McCormick et al., 2005). As expected,
UL36 strongly inhibited this type of apoptosis; apoptosis was
inhibited to a lesser extent also by UL37x1, and most potently by
the combination of both proteins.
In order to investigate whether UL36 and/or UL37x1 can
inhibit the cytotoxic function of T cells, we used CAR-T cells
directed against NKG2D ligands. Experiments with the gB-CAR
were not possible, since it was technically not feasible to generate
sufficient numbers of non-infected HFFs co-expressing HCMV-
gB, UL36, and UL37x1. Since non-infected HFFs in cell culture do
express NKG2D-ligands (Supplementary Figure S3B), we could
make use of our previously generated NKG2D-based CAR which
is highly potent in inducing NKG2D-ligand mediated killing
(Lehner et al., 2012). We considered this option straight forward,
since the key question of whether and which viral proteins block
cytotoxic T cell functions is not a matter of how efficiently those
cytotoxic functions are released.
Figure 5B shows apoptosis induction in the same non-infected
HFFs as used in the control experiments, now targeted by CAR-
T cells instead of the Fas agonistic antibody (CAR expression
is shown in Supplementary Figure S3A). Indeed, combined
expression of UL36 and UL37x1, and to a lesser extent of UL37x1
alone, significantly inhibited CAR-T cell cytotoxicity (p= 0.0177
and p= 0.0360, respectively). Notably, the potency of either UL36
or UL37x1 to inhibit T cell cytotoxicity was reversed compared
to Fas triggered apoptosis (Figure 5A), as the inhibitory effect
of UL37x1 was strong, and of UL36 was smaller and – in this
series of experiments – not significant. As previously analyzed,
αCD3/αCD28-activated T cells express perforin and granzymes
A, B, K, and M (Supplementary Figure S1E). Blockade of the
perforin/granzyme-mediated pathway in the T cells by adding
a saturating concentration of CMA, which inhibits acidification
of lytic granules and thereby accelerates degradation of perforin
(Kataoka et al., 1996), showed a predominant contribution
of this pathway (Figure 5B). Figure 5C compares the extent
of UL36/UL37x1-mediated inhibition of HFF apoptosis (gray
bars) with the proportion of apoptosis not inhibited by CMA
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FIGURE 4 | Lysis inhibition occurs with different HCMV-strains and also after extended co-culture period with the T cells. (A) Shown is the percentage
of apoptotic fibroblasts (non-infected or infected with recombinant HCMV-strains) after 4 and 20 h of co-culture with EBV-specific CTLs (E:T-ratio referring to
EBV-specific T cells = 20:1). Apoptotic cells were analyzed by staining with Annexin V by flow cytometry (n = 4, 4 different donors). (B) Shown is the percentage of
apoptotic target cells as indicated after 4 and 20 h of co-culture with CAR-expressing EBV-specific CTLs (n = 4, 4 different donors). Contrary to the analogous
experimental setup in (A), EBV-specific CTLs equipped with a gB-specific CAR vs. an irrelevant control-CAR were used for comparison instead of target cells
plus/minus peptide-loading. (C,D) Degranulation of EBV-specific CTLs after co-culture with the indicated target cells, as analyzed by flow cytometric detection of cell
surface expression of CD107a. (A–D) In all experiments HCMV-infected HFF were used 3 days after infection (MOI 5). (A,C) HFF were pulsed with 2 µg/ml of the
HLA-A∗0201 restricted EBV-BMLF1 peptide GLCTLVAML were indicated.
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FIGURE 5 | UL36 and UL37x1 inhibit CAR-T cell-mediated apoptosis in HFF. The anti-apoptotic HCMV-encoded proteins UL36 and UL37x1 were expressed
in HFF by either mRNA electroporation or retroviral transduction, respectively. (A) The anti-apoptotic function of the exogenously expressed proteins was confirmed
by overnight incubation of the HFF with cycloheximide (CHX, 10 µg/ml) plus an agonistic anti-Fas-antibody (0.2 µg/ml). A GFP encoding vector or
mock-electroporation were used as controls. The diagram shows the fraction of apoptotic HFF determined by Annexin V staining in a flow cytometric analysis
(n = 3). (B) The diagram shows the induction of cell death in HFF expressing UL36 and/or UL37x1 after 4 h of co-incubation with chNKG2D-expressing
αCD3/αCD28-activated T cells (n = 3, 3 different T cell donors). The percentages of apoptotic HFF obtained in the co-cultures of CAR-T cells plus HFF without
UL36/UL37x1 expression were set to 100%. Concanamycin A (CMA, 100 nM) was used to block perforin-induced apoptosis. (C) The diagram displays the
percentage of CAR-T cell-mediated apoptosis in HFF that was inhibited by the combined expression of UL36 and UL37x1 (gray bars; obtained by subtraction of the
respective values shown in (B) from 100%). The black bars show the proportion of CAR-T cell induced apoptosis in HFF, which was blocked by CMA (B) i.e., the cell
death that was not mediated by perforin/granzyme. If these values were a result of incomplete CMA blockade, then the black bars (non-perforin/granzyme mediated
cell death) would be even lower. The respective differences between the gray and the black bars correspond to the proportion of the perforin/granzyme-mediated
cell death in the HFF, which was inhibited by the combined expression of UL36 and UL37x1.
(black bars), i.e., the death-receptor and not perforin/granzyme
mediated proportion of cell death triggered by the CAR-
T cells. The large differences between the gray and black
bars illustrate that within the total of UL36/UL37x1-mediated
inhibition of CAR-T cell death (gray bars) there is a substantial
proportion of perforin/granzyme-mediated cell death. If CMA-
blockade of the perforin/granzyme pathway in these experiments
would have been incomplete, then the actual proportions of
death receptor-triggered apoptosis (black bars) would even
be smaller and the resulting differences (i.e., UL36/UL37x1-
inhibited perforin/granzyme-apoptosis) would even be larger.
When we repeated these experiments with EBV-specific CTLs,
which were directed via their TCR to peptide-loaded HFF,
expression of UL36/UL37x1 in the HFF had a pronounced
inhibitory effect with the T cells from one donor, which
interestingly secreted the lowest levels of IFN-γ wherease the
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T cells from the donor with the highest IFN-γ secretion could not
be blocked (Supplementary Figures S3D and S3E). Together, the
experiments with three donors showed no statistically significant
inhibitory effect of UL36/UL37x1. This was not unexpected, since
activation of EBV-specific CTLs in response to peptide-loaded
HFF possibly triggered maximum cytotoxicity and resulted in
significant lysis even 4 days after infection (Figures 3A and 4A),
whereas the same EBV-CTLs redirected via the gB-CAR were
activated less strongly (reflected in less degranulation; Figures 4D
vs. 4C) and could not trigger specific lyis (Figure 4B). The
fact that HCMV-infection significantly inhibits lysis even under
these conditions, whereas expression of UL36 and UL37 in
engineered non-infected HFF does not, suggests the existence of
yet unidentified further contributing anti-apoptotic factors.
The finding that combined expression of UL36 and UL37x1
in HFF could almost completely block cell death induction by
CAR-T cells is in line with our hypothesis that HCMV encoded
proteins not only block host cell suicide but also cytotoxic effector
functions of T cells.
DISCUSSION
Targeting of HCMV-infected cells in an HLA-independent
manner by CAR expressing T cells is attractive, because it
obviates the need for enriching antigen-specific memory T cells
and also circumvents one major immune evasion mechanism
employed by CMV, which leads to impaired antigen presentation
on infected cells by down-regulating HLA class I antigens.
Originally, this approach has been proposed for the treatment
of HIV using CARs of the first generation and was tested in
clinical phase II trials finally (Lam and Bollard, 2013). Recent
applications of a CAR T cell approach for fighting Hepatitis
B and C have shown promising results both in vitro and
in vivo in a preclinical model (Bohne et al., 2008; Krebs et al.,
2013; Sautto et al., 2016). We have analyzed the potential of
directing T cells against HCMV-infected fibroblasts by using a
CAR recognizing the HCMV gB (Full et al., 2010). However,
as reported in this manuscript, in depth studies with this CAR
revealed potent anti-apoptotic mechanisms of HCMV, which
apparently shield infected cells against cytotoxic effector cell
functions.
The Betaherpesvirus prototype HCMV is a complex virus
encoding up to 750 translational products in its genome (Stern-
Ginossar et al., 2012). Since many of these products are highly
immunogenic, HCMV triggers immune responses from all arms
of the immune system, resulting in a significant proportion
(median ∼10%, up to 40%) of the circulating CD8pos or CD4pos
T cell repertoire responding to HCMV-specific antigens T
cells (Crough and Khanna, 2009). Despite this strong T cell
reaction HCMV persists and establishes lifelong latency, possibly
explained by the fact that a large proportion of its genome
encodes for RNAs and proteins interfering with the antiviral
immune response. One of the most important and intensively
studied defense mechanisms of HCMV and its murine homolog
MCMV are the prevention of recognition of infected cells by
T and NK cells and by antibodies. Like many other viruses,
HCMV escapes recognition by T cells through interfering with
antigen processing and inhibiting antigen presentation by MHC
class I and II molecules on the surface of infected cells. In
HCMV this is mediated by the proteins US2, 3, 6, and 11, and
possibly by further factors including virus-encoded miRNAs.
The activation of NK cells, as a consequence of MHC class I
down-regulation and concomitant expression of stress-induced
ligands in infected cells, is impeded by down-regulating NK
cell activating ligands and by inducing inhibitory signals in the
NK cells (Noriega et al., 2012; Halenius et al., 2015). Finally,
HCMV is unique by encoding receptors for the Fc domains of all
subclasses of human IgG, thereby interfering with IgG-triggered
immune responses (Corrales-Aguilar et al., 2014). Together,
these mechanisms contribute to interference with recognition of
infected cells and the activation of immune effector T- and NK-
cells (Rolle et al., 2003; Manley et al., 2004; Tomasec et al., 2005;
Besold et al., 2007, 2009; Kim et al., 2011; Prod’homme et al.,
2012; Ameres et al., 2013).
We pursued an HLA-independent CAR approach, in order
to circumvent immune evasion by down-regulation of MHC
I antigen presentation, and also to avoid the need to expand
CMV specific T cells not readily available in high risk stem cell
transplantation between a seronegative donor and a seropositive
recipient. As target antigen we chose HCMV-gB, which is
abundantly expressed on the surface of infected cells and which is
conserved among different viral strains in the epitope recognized
by the CAR. Although our gB-specific CAR mediated effective
recognition of gB expressing cells, resulting in efficient lysis of
gB transfected 293T target cells and in T cell activation with
HVMC infected HFF target cells, neither αCD3/αCD28-activated
T cells nor more differentiated EBV-specific CTLs equipped with
this CAR could efficiently lyse HCMV-infected HFF. Inhibition
of target cell lysis was observed following fibroblast infection
with two well-characterized HCMV laboratory strains, i.e., Ad169
and Towne, and also after prolonged co-culture of infected and
effector T cells (Figure 4B). Further, we showed that this was not
a peculiarity of the CAR approach. Inhibition of lysis by HCMV
was also evident when an endogenous TCR was involved in T cell
triggering, as we demonstrated by using appropriate US-gene-
deleted HCMV-strains, EBV-specific T cells and EBV-peptide
loaded HCMV infected target cells (Figures 3B,C). Together
these experiments proved that HCMV blocks HLA-dependent
killing by directly inhibiting T cell cytotoxicity. Of note, despite
significant lysis inhibition in this peptide dependent experimental
system, there was some residual lysis even 4 days after infection
(Figure 3A), which we had not observed using gB specific CAR T
cells (Figure 1C). This could indicate suboptimal CAR function,
in particular, since also lower levels of secreted IFN-γ and
less pronounced degranulation were observed compared to the
experiments with peptide mediated TCR stimulation (Figures 2B
vs. 3C and 4D vs. 4C, respectively). An illustrative example of
such suboptimal CAR function resulting in decreased release of
effector functions are CARs directed against different epitopes of
CD22 (Haso et al., 2013). In interpretation of our data one needs
to consider moreover that EBV-specific CTLs were stimulated
via their TCR by an unphysiologically high concentration of
MHC:peptide complexes on the target cells.
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Our data show that HCMV evades the immune response
beyond impairing effector cell activation. To our knowledge, only
a single study with HCMV-infected astrocytoma cells targeted
by HCMV-specific CD4pos T cell clones previously indicated a
possible resistance to lysis despite T cell activation, but this was
not further investigated (Delmas et al., 2007). On the other hand,
while many studies addressed reactivity to peptide-pulsed cells,
lysis of HCMV-infected cells has been reported only occasionally.
In fact, infected cells can be targeted already early after entry of
HCMV through presentation of early expressed proteins such
as IE1, and also independently from endogenous viral gene
expression through presentation of peptides derived from the
ingested viral particles (Riddell et al., 1991; Reddehase, 2002;
Bunde et al., 2005; Terrazzini and Kern, 2014). Published findings
of efficient lysis of HCMV-infected cells might appear at first sight
to be in contrast to our observations reported in this paper, but
could be easily explained by differences in experimental setups
such as higher E:T-ratios or cytotoxicity assayed very early after
infection in these previous reports (Manley et al., 2004; Besold
et al., 2009; Ameres et al., 2013).
In search for a possible explanation for the observed resistance
to lysis we focused on previously described anti-apoptotic
factors encoded by HCMV. HCMV is a particular target of the
most ancestral antiviral defense mechanism, namely premature
elimination of infected cells by programmed cell death before
the viral replication cycle is complete. This is a consequence
of HCMVs slow sequentially ordered replication cycle. with
immediate-early, early and late phases of gene expression taking
3 days (Mocarski et al., 2013), a process which is paralleled
by exponentially increasing levels of viral protein (Reyda et al.,
2014), and finally the release of infectious HCMV particles
increasing in vitro until day 5 after infection (data not shown).
In order to prevent termination of viral replication by suicide of
its host cells, HCMV has integrated a whole array of repressors
blocking the host cell death machinery at several points (Brune,
2011). Anti-apoptotic activity has been described for three
HCMV-encoded proteins (UL36, UL37x1, and UL38) and the
viral miRNA β2.7 (Brune, 2011). Notably two of them, UL36
and UL37x1, inhibit death-receptor-induced cell death either
directly by binding of procaspase 8 in the case of UL36 or, in the
case of UL37x1, indirectly by sequestration of the pro-apoptotic
protein BAX, thereby preventing BID-induced cytochrome C
release from mitochondria and activation of executioner caspases
(Goldmacher et al., 1999; Skaletskaya et al., 2001; Arnoult
et al., 2004). UL37x1 is further known to inhibit HtrA2/Omi-
dependent programmed cell death and might be central for
evading host cell suicide (McCormick et al., 2008). The third
known protein involved in cell death suppression, UL38, reduces
ER stress by so far uncharacterized mechanisms and inhibits the
shutdown of the cellular metabolism (Terhune et al., 2007; Qian
et al., 2011).
We hypothesized that some of these anti-suicide mechanisms
could also inhibit T cell cytotoxicity and we thus investigated
the role of UL37x1 and UL36 in this context. Indeed, our
data confirmed our hypothesis, because expression of UL36
and UL37x1 in combination and even of UL37x1 alone
significantly inhibited the lysis of fibroblasts by CAR-T cells
(Figure 5B). Our data also show that a major fraction of
CAR-T cell cytotoxicity appeared to be mediated by the
perforin/granzyme pathway, since addition of CMA strongly
inhibited cell death induction (Figure 5B; Kataoka et al.,
1996). This pathway was also at least partially inhibited by
UL36/UL37x1 because the proportion of cell death, which
could not be blocked by CMA, i.e., the death-receptor-mediated
proportion (black bars in Figure 5C), was substantially smaller
than the proportion blocked by UL36/UL37x1 (gray bars in
Figure 5C).
Previously, a role for UL36 in counteracting T cell immunity
has been deduced from the ability to inhibit Fas-induced caspase-
8 activation (Skaletskaya et al., 2001). In our experiments with
cytotoxic T cells, however, UL37x1 appeared more protective
than UL36, which was opposite to their relative effects on
blocking Fas-induced apoptosis in the control experiments
(Figure 5A and Supplementary Figure S3C). The small effect of
UL36 in blocking T cell cytotoxicity compared to blocking Fas-
induced apoptosis might be explained by the large proportion
of granzyme-mediated T cell cytotoxicity, which seems to be
affected only by UL37x1. This makes it likely that particularly
this protein contributes to resistance of HCMV-infected cells
to T cell killing. Intriguingly, this matches with the essential
role of UL37x1 for host cell survival, which is reflected by the
100% identity of respective protein domains among HCMV-
strains (Hayajneh et al., 2001). UL36 seems to have only an
ancillary function in both, preventing host cell death and
blocking T cell cytotoxicity, since the UL36-deficient Ad169
strain in our experiments showed no increased host cell death
and efficiently blocked T cell cytotoxicity. Verification of the
hypothesis that UL37x1 has a function beyond preventing
host cell suicide by using an HCMV-mutant with inactive
UL37x1 was not possible due to extensive host cell death
already 3 days after infection before T cell cytotoxicity could be
assessed [(Reboredo et al., 2004) and data not shown]. However,
further experiments indicated that even multiple factors might
additionally contribute to block T cell cytotoxicity, because in
our model with strongly activated BMLF1-peptide specific CTLs
lysis was not significantly inhibited by the combined expression
of UL36/UL37 in non-infected HFF, whereas infection with
HCMV strongly inhibited lysis also under these conditions of
T cell activation (Figures 3A and 4A). These additional factors
could be other anti-apoptotic viral products, but could also
include host cell derived factors, such as, e.g., the granzyme
B inhibitor SERPINB9/PI-9 (Barrie et al., 2004). The fact
that even highly passaged laboratory strains of HCMV have
maintained the capacity to strongly inhibit T cell cytotoxicity
confirms our hypothesis that the involved factors might at the
same time prevent host cell suicide, which is essential also
in vitro.
In summary, our study shows that the Betaherpesvirus HCMV
efficiently shields its infected host cells from cytotoxic attack
not only by preventing HLA restricted cell recognition, but
additionally also by interfering with a cytotoxic attack through
functions of the viral anti-suicide machinery. It might well be
that similar mechanisms are effective also with other viruses as
many different viral anti-apoptotic proteins have been described
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so far. In our case it was the use of CAR-T cells, which led to
the discovery of this fundamental mechanism and of the ability
of UL37x1 to inhibit T cell killing. However, this mechanism
does not preclude potential anti-viral efficacy of CAR-T cells.
T effector cells also exert non-cytotoxic functions through
the secretion of antiviral cytokines and granzymes such as
granzyme M, which cleaves cellular and viral proteins important
for HCMV replication (van Domselaar et al., 2010, 2013).
Thus, HLA-independent targeting of HCMV through CAR
engrafted effector cells still seems attractive to pursue, particularly
in the case of HCMV-naïve/high risk immunosuppressed
patients.
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